Results per Page:
Crunching the numbers for next-gen COVID-19 vaccines
BARDA taps Fred Hutch biostatisticians to assess new vaccine technology, more nimble trial design
SARS-CoV-2 vaccine efficacy in Latin American countries
From the Gilbert Group, Vaccine and Infectious Disease and Public Health Sciences Divisions
When it comes to HPV vaccination, just once is enough
Galloway Lab, Human Biology Division
Learning to trust science with your life
Diseases like cancer and COVID-19 can be scary; leaning into the science helps you feel more empowered
New study highlights lack of diversity and inclusion in vaccine clinical trials
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed
Building trust in safe and effective COVID-19 vaccines
Convincing millions to get vaccinated will take more than data, facts and figures
Vaccines stop COVID-19 symptoms, but do they stop transmission?
Researchers mull options, including college dorm studies and 'human challenge' trials, to find answer
Public health’s pandemic pivot
With disease modeling, virtual events and a renewed focus on antiracism, Fred Hutch population scientists adapt their work to COVID-19
Obliteride brings in $2M to spur cancer, COVID-19 research
Annual Fred Hutch fundraiser goes virtual and DIY; sets records for participation, creativity and global reach
New HIV vaccine trial to launch in U.S., Latin America and Europe
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men
First licensed dengue vaccine withstands rainy season
From the Vaccine and Infectious Disease Division
New breast cancer vaccine ‘promising but not ready for prime time’
Vaccine potentially could be used in the majority of breast cancer patients
Fred Hutchinson Cancer Research Center and Seattle BioMed team up on malaria clinical trials
Studies to test drugs that may be useful for malaria treatment and prevention